TORONTO, ON / ACCESSWIRE / October 7, 2021 / GHP Noetic Science-Psychedelic Pharma Inc. (TSXV:PSYF.P) ("GHP"), a Capital Pool Company listed on the TSX Venture Exchange (the "Exchange"), is pleased to
/PRNewswire/ - Diamond Therapeutics Inc. ("Diamond"), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a .
BioXcel TherapeuticsFebruary 12, 2021 GMT
NEW HAVEN, Conn., Feb. 12, 2021 (GLOBE NEWSWIRE) BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the Company will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am ET to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine (“Dex”), and its potential as a treatment option for multiple neuropsychiatric conditions.